Table 1 Characteristics of included studies
Study | Study design | Cancer type | Age,mean (Intervention , Control) | Sample size (I ,C) | RA technique | PSM | Certainty of the evidence (GRADE) | length of follow up(month) |
|---|---|---|---|---|---|---|---|---|
Gupta 2011 | Retrospective cohort | Colorectal cancer | 71.4,73.2 | 655(562,93) | EA + GA | No | Low | 31 |
Wuethrich 2010 | Retrospective cohort | Prostate cancer | 63,64 | 261 | EA + GA | No | Low | 102 |
Li 2022 | RCT | Breast cancer | 48 ± 10 49 ± 9 | 1253 | PVB + GA | No | High | 53 |
de Oliveira 2011 | Retrospective cohort | Ovarian cancer | 55,57 | 183 | EA + GA | No | Low | 42 (IQR12-60) |
Mu 2021 | Retrospective cohort | Colorectal cancer | 60.5 ± 10.5, 61.2 ± 12.8 | 174 | EA + GA | Yes | Low | 41(IQR39-43) |
Tsui 2010 | RCT | Prostate cancer | 63.0 ± 5.5 63.9 ± 6.1 | 99 | EA + GA | No | High | 54 |
Wuethrich 2013 | Retrospective cohort | Prostate cancer | 63.8,63.6 | 148 | EA + GA | No | Low | 135 (IQR 14–198) |
Hasselager 2022 | Prospective cohort | Colorectal cancer | 70,70 | 5960 | EA + GA | Yes | Moderate | NA |
Macleod 2018 | Prospective cohort | Prostate cancer | 59.5,60 | 2909 | PVB + GA | No | Moderate | No multimodal analgesia:135 (IQR109–150) Multimodal analgesia: 55 (IQR29–83) |
Biki 2008 | Retrospective cohort | Prostate cancer | 63 ± 5, 62 ± 6 | 225 | EA + GA | No | Low | 33–153 |
Karmakar 2017 | RCT | Breast cancer | 52,51 | 177 | PVB + GA | No | High | 60 |
Sessler 2019 | RCT | Breast cancer | 53,53 | 2108 | EA/LA/SA + GA | No | High | 36 (IQR 24–49) |
Christopherson 2008 | RCT | Colorectal cancer | 68.6 ± 7.7, 69.1 ± 7.8 | 177 | EA + GA | No | High | NA |
Pei 2020 | Retrospective cohort | Gastric cancer | 65,75 | 194 | EA + GA | Yes | Low | NA |
Exadaktylos 2006 | Retrospective cohort | Breast cancer | NA | 129 | PVB + GA | No | Low | 32 ± 5 |
Gottschalk 2010 | Retrospective cohort | Colorectal cancer | 65,63 | 509 | EA + GA | No | Low | 21(IQR9-46) |
Kuo 2014 | Retrospective cohort | Hepatocellular carcinoma | 63.7 ± 10.7, 64.7 ± 11.7 | 118 | SA | No | Low | 24 |
Lai et al. 2012 | Retrospective cohort | Hepatocellular carcinoma | 51.5 ± 16.6, 54.9 ± 11.3 | 179 | EA | No | Low | 43(IQR2-129) |
Koumpan 2018 | Retrospective cohort | Bladder Cancer | 71.7 ± 10.5, 65.4 ± 10.5 | 243 | SA | No | Low | NA |
Tseng 2014 | Retrospective cohort | Prostate cancer | 58,58 | 1964 | SA | No | Low | 48 to 60 |
Heinrich 2015 | Retrospective cohort | Esophageal cancer | 61,61 | 153 | EA + GA | No | Low | NA |
Hiller 2014 | Retrospective cohort | Gastro-oesophageal cancer | 67,66 | 140 | EA + GA | No | Moderate | NA |
Holler 2013 | Retrospective cohort | Colorectal cancer | NA | 749 | EA + GA | No | Low | NA |
Zhang 2021 | Retrospective cohort | Breast cancer | 54.1, 54.1 | 2790 | PVB-RA | Yes | Low | patients receiving INHA-GA without propofol: 61.2 ± 25.2 patientsreceiving PB-RA with propofol: 62.1 ± 28.1 |
Sprung 2014 | Retrospective cohort | Prostate cancer | 63.9, 63.9 | 387 | EA | No | Low | NA |
Capmas 2012 | Retrospective cohort | Ovarian cancer | 56, 56 | 94 | EA + GA | No | Low | 33 to 153 |
Wang 2020 | Retrospective cohort | Hepatocellular carcinoma | 57.6, 56.1 | 489 | EA/LA/SA | No | Low | NA |
Choi 2017 | Retrospective cohort | Bladder Cancer | 63 ± 12, 61 ± 13 | 690 | SA | Yes | Low | 35 (IQR 11–57) |
Lu 2021 | Retrospective cohort | Breast cancer | 45, 45 | 169 | EA | No | Low | more than 60 |
Karanlik 2017 | Case-control | Breast cancer | 72.4 ± 6, 71.1 ± 3.7 | 91 | LA | No | Low | GA :55.09 ± 13.49 (IQR 38–104) LA: 58.7 ± 15.5 (IQR 20–99) |
Lin 2011 | Retrospective cohort | Ovarian cancer | 45.7, 48.1 | 143 | EA | No | Low | 24 to 174 |
Lee 2022 | Retrospective cohort | Bladder Cancer | 66.8 ± 6.1, 66.5 ± 6.1 | 1164 | EA/LA/SA | Yes | High | 53 ± 21 |